Lancet May 12, 2026

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

Deborah B Horn, Louis J Aronne, Sean Wharton, Harold E Bays, Carel W le Roux, Reshmi Srinath, et al.

Bottom Line

In adults with obesity, continuing tirzepatide at the maximum tolerated dose or de-escalating to a 5 mg dose effectively maintained prior weight loss, whereas switching to placebo resulted in substantial weight regain.

Key Findings

1. From baseline to week 112, the model-based estimate for percent change in body weight was -21.9% for the maximum tolerated dose (MTD) group, -16.6% for the 5 mg group, and -9.9% for the placebo group (p<0.0001 for all active vs. placebo comparisons) [4.1.4].

2. Participants who continued on the MTD maintained essentially all of their initial weight loss on average, while those de-escalated to 5 mg maintained all but an average of 5.6 kg of their prior weight loss.

3. Among participants who regained at least 50% of their lost body weight, rescue therapy was required by only 8% (11 of 138) in the MTD arm, compared to 25% (35 of 142) in the 5 mg arm and 67% (60 of 90) in the placebo arm.

4. Gastrointestinal events were the most common adverse events, mostly mild to moderate in severity, and predominantly occurred during the initial dose escalation phase.

Study Design

Design

RCT

Double-Blind

Sample

441

Patients

Duration

112 wk

Median

Setting

Multicenter, USA

Population Adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with ≥ 1 weight-related comorbidity (excluding type 2 diabetes) who achieved weight loss during a 60-week open-label tirzepatide run-in period.

Intervention Continued tirzepatide at the maximum tolerated dose (MTD: 10 mg or 15 mg) or step-down to tirzepatide 5 mg once weekly.

Comparator Placebo once weekly.

Outcome Percent change in body weight from baseline to week 112.

Study Limitations

• The allowance of rescue interventions—which was heavily utilized in the placebo arm (67%)—complicates the interpretation of the true, untreated natural history of weight regain and dilutes the observed magnitude of the placebo group's regain.

• Individual responses to stepping down to a 5 mg dose varied considerably, indicating that routine dose reduction may not be universally effective for all patients.

• The study population was geographically restricted to the USA, which may limit the generalizability of the findings to a broader, global population with diverse dietary and lifestyle backgrounds.

Clinical Significance

SURMOUNT-MAINTAIN provides critical evidence that obesity is a chronic disease requiring ongoing pharmacotherapy. While continuing the maximum tolerated dose offers the most robust long-term weight maintenance, de-escalating to a 5 mg maintenance dose serves as a viable, patient-centered alternative for those wishing to reduce medication exposure or side effects, despite mild weight regain.

Historical Context

The earlier SURMOUNT clinical trial program (SURMOUNT-1 through 4) established tirzepatide, a dual GIP/GLP-1 receptor agonist, as a highly efficacious agent for profound weight reduction. However, SURMOUNT-4 confirmed that completely stopping the drug leads to rapid weight regain. SURMOUNT-MAINTAIN was designed to answer the next major real-world clinical dilemma: whether patients who have achieved target weight loss can safely step down to a lower maintenance dose rather than remaining on the maximum dose indefinitely.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Tirzepatide is a dual agonist. What two receptors does it target, and what is the physiological rationale for why stopping the medication (as seen in the placebo group) leads to rapid weight regain?

Key Response

Tirzepatide targets GLP-1 and GIP receptors. Obesity is a chronic disease characterized by a disrupted biological set point. Stopping the medication removes incretin-mediated satiety signaling and delayed gastric emptying, allowing counter-regulatory hormones (like ghrelin) and central homeostatic mechanisms to drive hyperphagia and rapid weight regain.

Resident

A patient who achieved a 20 percent weight loss on tirzepatide 15 mg is experiencing persistent mild nausea and asks if they can stop or lower the dose. Based on the SURMOUNT-MAINTAIN trial, how would you counsel them regarding stopping versus de-escalating to 5 mg?

Key Response

Counsel the patient that stopping the medication entirely leads to substantial weight regain, reinforcing that obesity requires chronic treatment. However, de-escalating to a 5 mg maintenance dose effectively maintains prior weight loss, providing an evidence-based clinical strategy to alleviate dose-dependent adverse effects while preserving metabolic benefits.

Fellow

While de-escalating to a 5 mg dose maintains overall body weight comparably to the maximum tolerated dose, what specific long-term body composition and metabolic consequences should an obesity medicine specialist monitor during this de-escalation phase?

Key Response

Rapid weight loss often includes lean mass loss. A key clinical nuance is whether de-escalation prevents further muscle loss while maintaining fat loss, or if overall weight maintenance masks a subtle regain in fat mass offset by muscle loss. Monitoring body composition and cardiometabolic markers is crucial, as the lower dose might have different long-term durability than the maximum dose.

Attending

The finding that a lower de-escalated dose maintains weight loss introduces an induction-to-maintenance treatment paradigm for obesity. How does this conceptual shift alter our approach to the long-term tolerability and economic toxicity of anti-obesity medications?

Key Response

This mirrors treatment paradigms in other chronic diseases where high doses achieve remission and lower doses maintain it. Adopting this practice can significantly reduce patient side-effect burden, ease medication shortages, and potentially lower costs, making lifelong adherence to anti-obesity pharmacotherapy much more viable.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In assessing weight loss maintenance in a chronic de-escalation trial like SURMOUNT-MAINTAIN, how should researchers define the estimand framework to account for treatment discontinuation, and what bias is introduced if a purely per-protocol analysis is emphasized?

Key Response

Chronic weight trials suffer from attrition. Using a treatment-policy estimand reflects real-world effectiveness but may dilute the biological efficacy signal. A per-protocol or efficacy estimand isolates the biological effect of the 5 mg versus maximum dose but introduces selection bias by only including highly adherent patients, potentially overestimating real-world maintenance success.

Journal Editor

A major threat to validity in placebo-controlled trials of incretin therapies is functional unblinding due to distinct gastrointestinal side effects or rapid appetite changes. As an editor, how would you evaluate the impact of this unblinding on the behavioral components of weight maintenance across the study arms?

Key Response

Patients randomized to placebo likely realize quickly they are off the active drug due to the return of appetite and cessation of GI side effects. This functional unblinding can lead to nocebo effects or reduced adherence to lifestyle and dietary interventions, thereby exaggerating the magnitude of weight regain in the placebo group compared to what would happen in a truly blinded scenario.

Guideline Committee

Current obesity guidelines (e.g., AACE, AGA) emphasize the chronic nature of the disease and recommend long-term pharmacotherapy. How does the SURMOUNT-MAINTAIN evidence specifically warrant an update to these guidelines regarding structured dose de-escalation algorithms?

Key Response

Current guidelines strongly recommend chronic continuation of anti-obesity medications but offer little specific guidance on dose modulation for maintenance. The SURMOUNT-MAINTAIN data provides Level 1 evidence that structured de-escalation to a 5 mg dose is highly effective for maintenance, prompting guidelines to formally endorse induction and maintenance dosing strategies to balance efficacy, safety, and long-term adherence.

Clinical Landscape

Noteworthy Related Trials

2021

STEP 4 Trial

n = 803 · JAMA

Tested

Semaglutide 2.4mg weekly

Population

Adults with overweight or obesity

Comparator

Placebo

Endpoint

Percent change in body weight from week 20 to week 68

Key result: Participants continuing semaglutide experienced an additional 7.9% weight loss, whereas those switched to placebo regained 6.9% of body weight.

2022

SURMOUNT-1 Trial

n = 2,539 · NEJM

Tested

Tirzepatide 5, 10, or 15 mg weekly

Population

Adults with obesity or overweight without diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight from baseline to week 72

Key result: Tirzepatide yielded substantial and sustained reductions in body weight of up to 20.9% on the highest dose compared to placebo.

2023

SURMOUNT-4 Trial

n = 783 · JAMA

Tested

Tirzepatide maximum tolerated dose

Population

Adults with obesity or overweight without diabetes

Comparator

Placebo

Endpoint

Mean percent change in weight from week 36 to week 88

Key result: Continuing tirzepatide led to an additional 5.5% weight reduction, while switching to placebo resulted in a 14% weight regain.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis